<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289238</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125102157</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">US-CELGENEUS-163-21880-13013522</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20130121</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130121</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">US-CELGENEUS-163-21880-13013522</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <linkedreport>
      <linkreportnumb>US-CELGENE-163-21880-13010252</linkreportnumb>
    </linkedreport>
    <primarysource>
      <reportergivename>Robert</reportergivename>
      <reporterfamilyname>Waldmann</reporterfamilyname>
      <reporterstreet>43555 Dalcoma Drive, Suite 8, Attn: Linda, Nurse</reporterstreet>
      <reportercity>Clinton Township</reportercity>
      <reporterstate>MI</reporterstate>
      <reporterpostcode>48038</reporterpostcode>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>H-C</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19510905</patientbirthdate>
      <patientsex>1</patientsex>
      <patientmedicalhistorytext lang="en">None provided</patientmedicalhistorytext>
      <patientdeath>
        <patientdeathcause>
          <patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
          <patientdeathreport>10063378</patientdeathreport>
        </patientdeathcause>
      </patientdeath>
      <reaction>
        <primarysourcereaction lang="en">EXPIRED</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10011906</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10011906</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugauthorizationnumb>21-880</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugauthorizationholder>Celgene Corporation</drugauthorizationholder>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>21</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>21</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">25 Milligram</drugdosagetext>
        <drugdosageform lang="en">Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10028233</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20111118</drugstartdate>
        <actiondrug>6</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10011906</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Unknown</drugresult>
        </drugreactionrelatedness>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">EXPIRED

(USA) Initial information was received on 21/Jan/2013 from a nurse at the prescriber's office via a contract pharmacy regarding a 61 year old male who received Revlimid 25mg oral capsules once daily (21 every 21 days) from 18/Nov/2011 to an unknown date for the treatment of multiple myeloma without remission.  Lot number was A0177A and expiration date was 31/Jan/2015.  Relevant medical history and concomitant medications were unknown.

It was reported the patient had expired on an unspecifed date.  Cause of death was not provided.  It had previously been reported by the patient's caregiver that the patient was in a coma (MCN 163-21880-13010252).  The causal relationship of the patient's death to Revlimid was reported as unknown.  Additional information will be requested from the prescriber.  

This case was cross-referenced to MCN 163-21880-13010252 (coma, myocardial infarction).</narrativeincludeclinical>
        <sendercomment lang="en">The temporal relationship between therapy and the patient's death [EXPIRED] suggests that a causal relationship is possible, but underlying multiple myeloma could provide an alternative explanation. Additional information regarding the patient's disease status prior to death, relevant medical history, concomitant medications, and circumstances of the event will be requested.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
